2 completed, 1 active not recruiting, 1 withdrawn. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Withdrawn 1 |
Follow ripretinib: new trials by email Literature Review of ripretinib trials Research Report on ripretinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Inlexisertib, Ripretinib - GIST | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 94 | 2023-09-28 | 2026-10-20 |
| Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) Ripretinib, binimetinib - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Withdrawn | Deciphera Pharmaceuticals, LLC | 2021-11-01 | 2022-01-05 | |
| A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST Ripretinib, Repaglinide - GIST - Gastrointestinal Stromal Tumor | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 13 | 2021-09-22 | 2024-09-19 |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies DCC-2618 - Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 282 | 2015-11-01 | 2023-12-13 |
Gastrointestinal Stromal Tumors (4) · Carcinoma, Non-Small-Cell Lung (1) · Glioma (1) · Leukemia, Mast-Cell (1) · Mast Cell Activation Disorders (1) · Mastocytosis, Systemic (1) · Melanoma (1) · Neoplasms, Germ Cell and Embryonal (1) · Penile Neoplasms (1) · Renal Insufficiency (1) · Sarcoma (1)
Deciphera Pharmaceuticals, LLC (4)
United States (3) · Germany (2) · Italy (2) · Netherlands (2) · Canada (1) · Denmark (1) · France (1) · Portugal (1) · Spain (1) · Switzerland (1) · United Kingdom (1)